[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367946-105":59,"doc-detail-367946-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","comprehensive-pan-cancer-analysis-of-krt6a-as-a-prognostic-and-immune-biomarker","Comprehensive pan-cancer analysis of KRT6A as a prognostic and immune biomarker","","Keratin 6A (KRT6A) is implicated in tumor occurrence and development, yet a human pan-cancer characterization was lacking. The study integrates multiple public datasets (TCGA, GTEx, HPA, TIMER2.0, UALCAN, TISIDB, GEPIA2, Kaplan-Meier Plotter, cBioPortal, and TISCH2) and performs immunohistochemistry to assess KRT6A in lung adenocarcinoma versus adjacent normal tissues. Results show differential KRT6A mRNA and protein expression across many tumors, linked to DNA methylation, RNA methylation, phosphorylation, prognosis, and clinical subtypes, and associated with TMB, MSI, TSC, immune checkpoints, immunomodulatory genes, and the tumor immune microenvironment; LUAD validation indicates KRT6A upregulation promotes tumor progression and suggests biomarker and immunotherapy target potential.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-pan-cancer-analysis-of-krt6a-as-a-prognostic-and-immune-biomarker/367946/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-pan-cancer-analysis-of-krt6a-as-a-prognostic-and-immune-biomarker/367946.png","ImageObject",300,407,{"name":92,"@type":93},"Guten tag","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"Why is KRT6A important for cancer research?","Question",{"text":113,"@type":114},"KRT6A participates in tumor occurrence and development, and evidence links it to structural and regulatory roles in epithelial tissues. However, a comprehensive pan-cancer analysis in humans had been insufficient prior to this work.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was KRT6A analyzed across cancers?",{"text":118,"@type":114},"The study used multiple external public databases (including TCGA and GTEx) to assess differential expression and related clinical outcomes. Immunohistochemistry was used to validate KRT6A protein expression in lung adenocarcinoma and adjacent normal tissues.",{"name":120,"@type":111,"acceptedAnswer":121},"What immune-related features is KRT6A associated with?",{"text":122,"@type":114},"KRT6A expression correlates with tumor mutation burden (TMB), microsatellite instability (MSI), tumor stemness score (TSC), immune checkpoints, immunomodulatory genes, and the tumor immune microenvironment (TIME). It is also linked to immunotherapy and drug sensitivity.",{"name":124,"@type":111,"acceptedAnswer":125},"What did validation in LUAD show?",{"text":126,"@type":114},"KRT6A mRNA and protein were upregulated in LUAD compared with adjacent normal tissues. The findings indicate KRT6A can promote LUAD progression by influencing processes such as epidermis development, intermediate filament cytoskeleton, and cornified envelope formation.","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},367946,1790210579,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":81,"preview_urls":151},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nComprehensive pan-cancer analysis of KRT6A as a prognostic and immune biomarker  \nYan Lv1,2, Xinji Liu1,2, Zhihan Xiao1,2, Xu Zhan1, Wei Tang1, Qihang Sun1, Qi Wang1, Ruijie Zhang1, Wei Ping1􀀍 & Ni Zhang1􀀍  \nKeratin 6 A (KRT6A) is a member of the keratin family and can participate in the occurrence and development of some tumors. However, there is still a lack of pan-cancer analysis of KRT6A in humans. We studied the pan-cancer role of KRT6A with the help of a variety of external public databases (mainly including TCGA, GTEx, HPA, TIMER2.0, UALCAN, TISIDB, GEPIA2, Kaplan-Meier Plotter, cBioPortal and TISCH2, etc.). We performed immunohistochemistry detection of KRT6A protein expression in lung adenocarcinoma (LUAD) and its adjacent normal tissues. The results showed that KRT6A mRNA and protein were differentially expressed in most tumors, and its expression and function may be regulated by DNA methylation, RNA methylation and protein phosphorylation, and were related to the prognosis and clinical subtypes of patients with different tumors. KRT6A has multiple genetic and epigenetic characteristics in different cancers, and the main type of its genetic variation is mutation. At the same time, KRT6A is closely related to tumor mutation burden (TMB), microsatellite instability (MSI), tumor stemness score (TSC), immune checkpoints, immunomodulatory genes, and tumor immune microenvironment (TIME) in different human tumors. Secondly, the expression level of KRT6A is associated with immunotherapy and drug sensitivity. In addition, bioinformatics analysis and immunohistochemistry experiments verified that KRT6A mRNA and protein were up-regulated in LUAD, and could promote the development process of LUAD by promoting processes such as epidermis development, intermediate filament cytoskeleton and cornified envelope. This is the first pan-cancer analysis of KRT6A, which provides a comprehensive and systematic understanding of its role in various human tumors, and also reveals that KRT6A is expected to become a potential prognostic biomarker and a new target for cancer immunotherapy.  \nKeywords KRT6A, Pan-cancer, Prognosis, Immunity, Biomarker, Bioinformatics  \nTo date, cancer remains a leading cause of death in humans and a public health problem facing the international community, with a huge negative impact on social health and economic livelihood around the world1–5. With more and more scholars investing in the research and exploration of tumor-related fields, targeted therapy and immunotherapy and other treatment methods have been continuously updated and improved, and the actual treatment effect of various tumors has been greatly improved6,7. However, due to the heterogeneity of tumors, clonal evolution, immune escape, and treatment resistance, the overall cure rate and survival prognosis of cancer patients are still unsatisfactory8,9. Therefore, the exploration and development of new and highly potential pancancer diagnostic and prognostic biomarkers and cancer treatment targets are still an important part of the current tumor diagnosis and treatment field10. At present, with the continuous development of high-throughput technology, people can use a variety of large-scale external public databases (such as TCGA and GTEx) to conduct systematic and comprehensive pan-cancer analysis, explore the correlation between differential expression of target genes and pan-cancer-related clinical features and patient survival prognosis, and provide a certain basis for the discovery of new promising biomarkers11–15. Therefore, bioinformatics analysis is often used in the study of gene expression in human pan-cancer to explore potential targets for clinical diagnosis and treatment of cancer16–18.  \nKeratin 6 A (KRT6A) is a gene encoding type II keratin, which belongs to the keratin family and plays an important role in the structural support and functional regulation of ","cbCaie9oLeIhUGpL","https://ap.wps.com/l/cbCaie9oLeIhUGpL","pdf",14222255,27,"English","# Overview\n## Rationale and research gap\n# Data and methods\n## Public database integration\n## Immunohistochemistry validation in LUAD\n# Key findings\n## Differential expression and regulatory mechanisms\n## Associations with prognosis and clinical subtypes\n## Links to TMB, MSI, TSC, immune checkpoints, and TIME\n## Relationships with immunotherapy and drug sensitivity\n# Functional and pathway insights\n## LUAD biological process promotion\n## Cross-cancer and example evidence\n# Significance\n## Pan-cancer understanding and clinical potential","[{\"question\":\"Why is KRT6A important for cancer research?\",\"answer\":\"KRT6A participates in tumor occurrence and development, and evidence links it to structural and regulatory roles in epithelial tissues. However, a comprehensive pan-cancer analysis in humans had been insufficient prior to this work.\"},{\"question\":\"How was KRT6A analyzed across cancers?\",\"answer\":\"The study used multiple external public databases (including TCGA and GTEx) to assess differential expression and related clinical outcomes. Immunohistochemistry was used to validate KRT6A protein expression in lung adenocarcinoma and adjacent normal tissues.\"},{\"question\":\"What immune-related features is KRT6A associated with?\",\"answer\":\"KRT6A expression correlates with tumor mutation burden (TMB), microsatellite instability (MSI), tumor stemness score (TSC), immune checkpoints, immunomodulatory genes, and the tumor immune microenvironment (TIME). It is also linked to immunotherapy and drug sensitivity.\"},{\"question\":\"What did validation in LUAD show?\",\"answer\":\"KRT6A mRNA and protein were upregulated in LUAD compared with adjacent normal tissues. The findings indicate KRT6A can promote LUAD progression by influencing processes such as epidermis development, intermediate filament cytoskeleton, and cornified envelope formation.\"}]","Comprehensive pan-cancer analysis of KRT6A as a prognostic and immune biomarker | PDF",1790173479,68,[152,156,160],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/0e1e11af89d847a06717ade25433b057.webp",983,1291,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/5777a8803b6c709b7125b2db119eee11.webp",982,1290,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/aabf7b057238c57019e3ff611f1c10c7.webp",981,1289]